×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KZR – kezar life sciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KZR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
01:09 am
kzr
Kezar Life Sciences GAAP EPS of -$1.53 beats by $0.42 [Seeking Alpha]
Low
Report
Kezar Life Sciences GAAP EPS of -$1.53 beats by $0.42 [Seeking Alpha]
11/12
04:01 pm
kzr
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
Low
Report
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
11/7
07:01 am
kzr
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
Low
Report
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
10/18
07:31 am
kzr
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "strong sell" rating.
Low
Report
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "strong sell" rating.
10/17
08:46 am
kzr
Kezar Life Sciences (NASDAQ:KZR) had its "market perform" rating reaffirmed by analysts at William Blair.
High
Report
Kezar Life Sciences (NASDAQ:KZR) had its "market perform" rating reaffirmed by analysts at William Blair.
10/17
08:06 am
kzr
Kezar Life Sciences (NASDAQ:KZR) was given a new $5.00 price target on by analysts at Wells Fargo & Company.
Medium
Report
Kezar Life Sciences (NASDAQ:KZR) was given a new $5.00 price target on by analysts at Wells Fargo & Company.
10/17
06:03 am
kzr
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at Jefferies Financial Group Inc. to a "hold" rating.
High
Report
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at Jefferies Financial Group Inc. to a "hold" rating.
10/16
04:33 pm
kzr
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives [Yahoo! Finance]
Medium
Report
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:01 pm
kzr
kezar life sciences, inc.
BEAT
Report
-0.1%
kezar life sciences, inc.
3/25/2025
07:30 am
kzr
kezar life sciences, inc.
MISS
Report
-10.5%
kezar life sciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
01:33 pm
kzr
Form SCHEDULE 13G/A Kezar Life Sciences, Filed by: Avidity Partners Management LP
Low
Report
Form SCHEDULE 13G/A Kezar Life Sciences, Filed by: Avidity Partners Management LP
11/12
04:22 pm
kzr
Form 10-Q Kezar Life Sciences, For: Sep 30
Low
Report
Form 10-Q Kezar Life Sciences, For: Sep 30
11/12
04:08 pm
kzr
Form 8-K Kezar Life Sciences, For: Nov 12
Low
Report
Form 8-K Kezar Life Sciences, For: Nov 12
11/7
04:21 pm
kzr
Form 8-K Kezar Life Sciences, For: Nov 06
Low
Report
Form 8-K Kezar Life Sciences, For: Nov 06
10/22
04:19 pm
kzr
Form 8-K Kezar Life Sciences, For: Oct 20
Low
Report
Form 8-K Kezar Life Sciences, For: Oct 20
10/16
04:23 pm
kzr
Form 8-K Kezar Life Sciences, For: Oct 16
High
Report
Form 8-K Kezar Life Sciences, For: Oct 16
9/8
05:45 pm
kzr
Form SCHEDULE 13G Kezar Life Sciences, Filed by: Stonepine Capital Management, LLC
Low
Report
Form SCHEDULE 13G Kezar Life Sciences, Filed by: Stonepine Capital Management, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/5
Form 4 Kezar Life Sciences, For: Feb 04 Filed by: Economides Vassiliki
28.2%
1/30 Form 8-K Kezar Life Sciences, For: Jan 30 26.9%
2/10 Form SC 13G/A Kezar Life Sciences, Filed by: AMGEN INC 24.0%
4/9 Kezar Provides Statement Regarding COVID-19 Pandemic 9.7%
12/19 Form 3 Kezar Life Sciences, For: Dec 18 Filed by: Garner Elizabeth 8.4%
6/27 Form 4 Kezar Life Sciences, For: Jun 25 Filed by: BERGER FRANKLIN M 7.5%
10/1 Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting 6.8%
12/19 Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors 6.3%
8/12 Form 4 Kezar Life Sciences, For: Aug 09 Filed by: Fowler John Franklin 6.2%
12/20 Form 4 Kezar Life Sciences, For: Dec 19 Filed by: Fowler John Franklin 5.7%
1/30 Form 8-K Kezar Life Sciences, For: Jan 30 26.9%
2/10 Form SC 13G/A Kezar Life Sciences, Filed by: AMGEN INC 24.0%
4/9 Kezar Provides Statement Regarding COVID-19 Pandemic 9.7%
12/19 Form 3 Kezar Life Sciences, For: Dec 18 Filed by: Garner Elizabeth 8.4%
6/27 Form 4 Kezar Life Sciences, For: Jun 25 Filed by: BERGER FRANKLIN M 7.5%
10/1 Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting 6.8%
12/19 Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors 6.3%
8/12 Form 4 Kezar Life Sciences, For: Aug 09 Filed by: Fowler John Franklin 6.2%
12/20 Form 4 Kezar Life Sciences, For: Dec 19 Filed by: Fowler John Franklin 5.7%
TOP News Decliners
5/28
Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
-34.0%
2/26 Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference -14.2%
2/7 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -12.9%
6/13 Form 8-K Kezar Life Sciences, For: Jun 13 -12.5%
11/12 Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting -11.2%
3/10 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -11.0%
10/1 Kezar Life Sciences Inc (NASDAQ: KZR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -10.1%
3/14 Kezar Life Sciences Inc (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at William Blair. -7.7%
3/13 Kezar Life Sciences Inc (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Co from $30.00 to $18.00. They now have an "overweight" rating on the stock. -7.4%
6/25 Form 8-K Kezar Life Sciences, For: Jun 25 -7.1%
2/26 Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference -14.2%
2/7 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -12.9%
6/13 Form 8-K Kezar Life Sciences, For: Jun 13 -12.5%
11/12 Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting -11.2%
3/10 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -11.0%
10/1 Kezar Life Sciences Inc (NASDAQ: KZR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -10.1%
3/14 Kezar Life Sciences Inc (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at William Blair. -7.7%
3/13 Kezar Life Sciences Inc (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Co from $30.00 to $18.00. They now have an "overweight" rating on the stock. -7.4%
6/25 Form 8-K Kezar Life Sciences, For: Jun 25 -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: